申请人:Pfizer Inc.
公开号:US04351940A1
公开(公告)日:1982-09-28
2,4-Diaminoquinazolines of the formula ##STR1## wherein Y.sup.1 is hydrogen or chloro, Y.sup.2 is OR, Y.sup.3 is hydrogen or OR such that when Y.sup.1 is hydrogen, Y.sup.3 is OR and when Y.sup.1 is chloro, Y.sup.3 is hydrogen or OR, and the pharmaceutically acceptable salts thereof; R represents an alkyl group having from one to three carbon atoms; taken separately, R.sup.1 and R.sup.2 are each hydrogen, alkyl having from one to five carbon atoms, cycloalkyl having from three to eight carbon atoms, alkenyl or alkynyl each having from three to five carbon atoms or hydroxy substituted alkyl having from two to five carbon atoms, when taken together with the nitrogen atom to which they are attached R.sup.1 and R.sup.2 form a substituted or unsubstituted heterocyclic group optionally containing an atom of oxygen, sulfur or a second atom of nitrogen as a ring member; their use as antihypertensive agents, pharmaceutical compositions containing them and intermediates for their production.
公式为 ##STR1## 的2,4-二氨基喹嗪,其中Y1为氢或氯,Y2为OR,Y3为氢或OR,当Y1为氢时,Y3为OR,当Y1为氯时,Y3为氢或OR,以及其药学上可接受的盐;R代表具有1至3个碳原子的烷基;分别取R1和R2为氢、具有1至5个碳原子的烷基、具有3至8个碳原子的环烷基、具有3至5个碳原子的烯基或炔基或具有2至5个碳原子的羟基取代的烷基,当它们与它们所连接的氮原子一起取用时,R1和R2形成一个取代或未取代的杂环基,可选地含有一个氧原子、硫原子或第二个氮原子作为环成员;它们作为降压剂的用途,包含它们的制药组合物和它们制备的中间体。